Cite
MLA Citation
Roy Fleischmann et al.. “Safety and efficacy of elsubrutinib or upadacitinib alone or in combination (ABBV-599) in patients with rheumatoid arthritis and inadequate response or intolerance to biological therapies: a multicentre, double-blind, randomised, controlled, phase 2 trial.” Lancet, vol. 4, 2022, pp. e395–e406. http://access.bl.uk/ark:/81055/vdc_100155168771.0x000001